Most Recent Additions*
"Oncologic Safety of Staged Pre-Pectoral Implant Reconstruction Following Nipple-Sparing Mastectomy: a Mean 9-Year Follow-Up."
Arthur H Salibian and Jay K Harness
Phase III Randomized Trial of Maintenance Taxanes Versus Surveillance in Women With Advanced Ovarian/Tubal/Peritoneal Cancer: A Gynecologic Oncology Group 0212:NRG Oncology Study.
Larry J Copeland, Mark F Brady, Robert A Burger, William H Rodgers, Helen Q Huang, David Cella, David M O'Malley, Daron G Street, Krishnansu S Tewari, David P Bender, Robert T Morris, William J Lowery, David S Miller, Summer B Dewdney, Nick M Spirtos, Shashikant B Lele, Saketh Guntupalli, Frederick R Ueland, Gretchen E Glaser, Robert S Mannel, and Philip J DiSaia
A phase 1b, multicenter, dose-escalation study of subasumstat (TAK-981) in combination with pembrolizumab in patients (pts) with advanced solid tumors.
Sanjay Goel, Rachel E Sanborn, and See full list of authors in comments
A phase 2 study of an off-the-shelf, multi-neoantigen vector (ADXS-503) in patients with metastatic non–small cell lung cancer either progressing on prior pembrolizumab or in the first-line setting.
Gregory James Gerstner, Rachel E Sanborn, and See full list of authors in comments
A phase II trial of TGFβ type I receptor inhibitor, galunisertib, plus neoadjuvant chemoradiation in patients with locally advanced rectal cancer.
Kristina H Young, Walter Urba, Michael J. Gough, Marka R Crittenden, and See full list of authors in comments
Recommended phase 2 dose (RP2D) of HB-200 arenavirus-based cancer immunotherapies in patients with HPV16+ cancers.
Siqing Fu, Rom Leidner, and Matthew H Taylor
A single-arm, phase 2 study of perioperative ipilimumab, nivolumab, and cryoablation in women with hormone receptor-negative, HER2-negative, early-stage/resectable breast cancer.
Heather L. McArthur, David B Page, and See full list of authors in comments
TAK-676 in combination with pembrolizumab after radiation therapy in patients (pts) with advanced non–small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), or squamous-cell carcinoma of the head and neck (SCCHN): Phase 1 study design.
Benjamin T. Cooper and David B Page
Virtual Reality Tour of the Operating Theater as Anxiolysis for Pediatric Cardiology Procedures
Nathan Brown
Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial.
EMPA-KIDNEY Collaborative Group and Katherine Tuttle (EMPA-KIDNEY Collaborative Group)
A glomerular transcriptomic landscape of apolipoprotein L1 in Black patients with focal segmental glomerulosclerosis.
Michelle T McNulty, Damian Fermin, Felix Eichinger, Dongkeun Jang, Matthias Kretzler, Noël P Burtt, Martin R Pollak, Jason Flannick, Astrid Weins, David J Friedman, Nephrotic Syndrome Study Network (NEPTUNE), and Matthew G Sampson
GLP-1 Receptor Agonists in the Treatment of Patients with Type 2 Diabetes and Chronic Kidney Disease
Joshua J. Neumiller, Radica Alicic, and Katherine R. Tuttle
Beyond Checkpoint Inhibitors: Enhancing Antitumor Immune Response in Lung Cancer
Rachel E Sanborn and See full list of authors in comments
Dose escalation of davoceticept, a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies (NEON-1)
Diwakar Davar, Rachel E Sanborn, and See full list of authors in comments
Identification of clinically actionable biomarkers via routine comprehensive genomic profiling across a large community health system
Roshanthi Weerasinghe, Ryan Meng, Alexa K Dowdell, Bela Bapat, Ann Vita, Brock Schroeder, Alisha Stein, Lauren Harold, Mark Schmidt, Shu-Ching Chang, Thomas R. Ward, Josiah T Wagner, Stanley Piotrowski, Phillip G. Febbo, Carlo Bifulco, and Brian D. Piening
Interim results of an ongoing phase 1/2a study of HPN328, a tri-specific, half-life extended, DLL3-targeting, T-cell engager, in patients with small cell lung cancer and other neuroendocrine cancers.
Melissa Lynne Johnson, Rachel E Sanborn, and See full list of authors in comments
Neoadjuvant HER2-targeted therapy +/- immunotherapy with pembrolizumab (neoHIP): An open-label randomized phase II trial.
Heather L. McArthur, David B Page, and See full list of authors in comments
Neoadjuvant survivin-targeted immunotherapy maveropepimut-S (MVP-S) to increase Th1 immune response in Ki67-high hormone receptor-positive (HR+) early-stage breast cancer (ESBC).
Sasha Stanton, Kristina H Young, David B Page, and See all authors in comments
Outcomes by tobacco history in E3311, a phase II trial of transoral surgery (TOS) followed by pathology-based adjuvant treatment in HPV-associated (HPV+) oropharynx cancer (OPC): A trial of the ECOG-ACRIN Cancer Research Group.
Ranee Mehra, Richard Bryan Bell, and See full list of authors in comments
*Updated as of 08/11/22.
